Loading...
The document provides gross profit margin ratios for Celgene products, Amgen product, BRUKINSA®, and Tislelizumab for different periods. It highlights the financial information prepared in accordance with both PRC GAAP and U.S. GAAP.
Gross profit margin ratios are provided for Celgene products from 2017 to September 30, 2020.
Gross profit margin ratio for Amgen product is available for the nine months ended September 30, 2020.
BRUKINSA® gross profit margin ratios are provided for the nine months ended September 30, 2020 and the year ended December 31, 2019.
Tislelizumab gross profit margin ratio is available for the nine months ended September 30, 2020.
No forward guidance was provided in the document.